The Discounted Cash Flow (DCF) valuation of Immunitybio Inc (IBRX) is (984.04) USD. With the latest stock price at 7.70 USD, the upside of Immunitybio Inc based on DCF is -12879.7%.
Based on the latest price of 7.70 USD and our DCF valuation, Immunitybio Inc (IBRX) is a sell. selling IBRX stocks now will result in a potential gain of 12879.7%.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| WACC / Discount Rate | 6.4% - 8.3% | 7.4% |
| Long-term Growth Rate | 3.0% - 5.0% | 4.0% |
| Fair Price | (2,339.88) - (630.36) | (984.04) |
| Upside | -30488.1% - -8286.5% | -12879.7% |